Indonesia's Kalbe Farma has opened a $35 million plant near Jakarta to produce biologics for the local market.

CDMO Almac, which has been bulking up its capacity and services, has opened a new cold storage facility at its Northern Ireland headquarters campus.

Fresenius’ $4.3 billion buyout of generics maker Akorn is in jeopardy as they investigate allegations that Akorn violated FDA drug development standards.

Jazz Pharmaceuticals has released new vials of Erwinaze, its leukemia drug for children, that came into short supply in 2016.

After years of effort and a couple of reinspections, India’s Sun Pharma has been unable to satisfy the FDA's expectations for its key plant.

Swedish CDMO Recipharm grews sales significantly last year but recorded a loss for the year as its rapid expansion took a toll.

Merck KGaA, which has been rapidly building up its manufacturing and distribution capabilities in China, says it will now expand further in Asia.

GlaxoSmithKline is again having manufacturing issues with some of its inhalers, leading it to voluntarily recall products in markets outside the U.S.…